Alerts will be sent to your verified email
Verify Email
TORNTPHARM
|
Torrent Pharma
|
Mankind Pharma
|
Cipla
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
168.0 . | 60.0 . | 283.0 . |
|
Number of ANDA's Approved By USFDA
|
132.0 . | 44.0 . | 204.0 . |
|
Domestic Sales Growth - YoY
|
12.8 % | n/a | 7.1 % |
|
R&D as a % of Total Sales
|
5.4 % | 2.15 % | 5.1 % |
|
Financials
|
|||
|
5 yr Average ROE
|
20.0 % | 23.46 % | 12.48 % |
|
5yr average Equity Multiplier
|
2.34 | 1.37 | 1.31 |
|
5yr Average Asset Turnover Ratio
|
0.65 | 0.95 | 0.78 |
|
5yr Avg Net Profit Margin
|
13.21 % | 17.9 % | 12.29 % |
|
Price to Book
|
14.99 | 10.16 | 4.42 |
|
P/E
|
60.42 | 52.6 | 25.11 |
|
5yr Avg Cash Conversion Cycle
|
-189.03 Days | -44.05 Days | -4.58 Days |
|
Inventory Days
|
54.5 Days | 58.78 Days | 58.34 Days |
|
Days Receivable
|
41.38 Days | 24.18 Days | 45.49 Days |
|
Days Payable
|
318.84 Days | 130.75 Days | 110.05 Days |
|
5yr Average Interest Coverage Ratio
|
5.79 | 56.97 | 33.93 |
|
5yr Avg ROCE
|
23.72 % | 30.07 % | 17.45 % |
|
5yr Avg Operating Profit Margin
|
29.52 % | 24.6 % | 21.56 % |
|
5 yr average Debt to Equity
|
0.83 | 0.05 | 0.07 |
|
5yr CAGR Net Profit
|
10.08 % | 13.17 % | 21.66 % |
|
5yr Average Return on Assets
|
8.58 % | 17.12 % | 9.64 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
68.31 % | 72.7 % | 29.2 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-2.94 % | -3.8 % | -4.43 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-2.45 % | 5.84 % | 6.6 % |
|
Torrent Pharma
|
Mankind Pharma
|
Cipla
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Acute vs Chronic
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|